Generation of a Complete Set of Precise Null Bar-Coded Deletion Mutants of Mycobacterium tuberculosis

结核分枝杆菌一整套精确空条形码缺失突变体的生成

基本信息

批准号：
10556037
负责人：
WILLIAM Robert JACOBS
金额：
$ 76.45万
依托单位：
ALBERT EINSTEIN COLLEGE OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-14 至 2028-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10556037
关键词：
Acceleration Alleles Attenuated Bacillus Bacteriophages Bar Codes Biology COVID-19 pandemic CRISPR library Caring Cessation of life Collection Communities Containment DNA Data Developing Countries Development Diagnosis Discipline Electroporation Engineering Epidemic Extreme drug resistant tuberculosis Foundations Fright Gene Deletion Gene Family Gene Frequency Gene Targeting Generations Genes Genetic Genome Genotype Goals Growth HIV Immunologics International M. tuberculosis genome Metabolism Methodology Molecular Genetics Morbidity - disease rate Multidrug-Resistant Tuberculosis Mutagenesis Mycobacteriophages Mycobacterium smegmatis Mycobacterium tuberculosis Mycobacterium tuberculosis H37Rv Nucleotides Persons Phenotype Physiology Plasmids Process Proteins Protocols documentation Publications Quality Control Reagent Recombinants Research Research Personnel Resources Source Tuberculosis Vaccines Virulent chemotherapy cost effective genetic manipulation genome-wide global health health inequalities improved knockout gene manufacturing scale-up mortality mutant mycobacterial null mutation pathogen success therapeutic target therapeutically effective therapy development tuberculosis diagnostics vector

项目摘要

Project Abstract Tuberculosis (TB) continues to be a major global health problem with 9 million new cases per year resulting in 1.7 million deaths, due in large part to the HIV epidemic and emergence of multi- and extensively drug resistant TB strains (MDR- and XDR-TB) that have confounded TB control. There will be no lasting reduction of TB morbidity and mortality without rapid and cost-effective TB diagnostics, efficacious vaccines, and shortened, well-tolerated chemotherapy, which can only be developed on the foundation of understanding the biology of the tubercle bacilli and subsequent host-pathogen interactions. The goal of this proposal is to accelerate TB research through the completion and distribution of 4,000 specialized transducing reagents to make precise null bar-coded deletion (PNBCD) mutants in every gene of M. tuberculosis. We plan to make mutants in virulent Mtb strains and mc27902, an attenuated Mtb strain that can be used under BSL2-containment. We will partner with ATCC (BEI) for distribution of these and distribution

项目摘要结核病（TB）仍然是全球重大的健康问题，有900万个新的问题每年案件导致170万人死亡，这在很大程度上是由于艾滋病毒的流行和多种和广泛的抗药性结核病菌株（MDR-和XDR-TB）的出现有混淆结核病控制。 TB发病率不会持久降低死亡率没有快速且具有成本效益的结核病诊断，有效的疫苗和缩短，耐受良好的化学疗法，只能在基础上开发了解结核细菌的生物学和随后的宿主病原互动。该提案的目的是通过完成和分配4,000种专业过渡试剂，以精确结核分枝杆菌的每个基因中的无条形编码缺失（PNBCD）突变体。我们计划在有毒的MTB菌株和MC27902中制造突变体，这是一种可减毒的MTB菌株在BSL2-containment下使用。我们将与ATCC（BEI）合作分发这些和分布